Autonomix Investigates Novel Approach to Treating Pancreatic Cancer

Medical device company, Autonomix Medical, Inc. (Nasdaq: AMIX) has successfully completed an animal study evaluating the ability of targeted nerve ablation to impact tumor metastases and growth. The company’s share price rose on Friday in response to the news. Autonomix is developing its catheter-based sensing technology to address pancreatic cancer-related pain. Current approaches, which primarily… [Read More]

This Week’s PRISM Market Recap: The Bull and Bear Report

This week, earnings wrapped up with additional major retail reports and included the highly anticipated NVIDIA (NVDA) announcement while further economic commentary was released. Some normalcy is expected to return next week as companies attend conferences and scheduled macro news slows. Market data and observations are constantly in motion each day, but what dictates the… [Read More]

BranchOut Food Purchases Third EnWave Machine to Meet Increasing Demand from US Retailers

Leading food technology company, BranchOut Food (Nasdaq: BOF) has expanded its partnership with EnWave Corporation with the purchase of a third large-scale EnWave dehydration machine. The addition is strategically aimed at expanding its new facility in Peru, which the company says has an estimated $40 million in production capacity with 40-50% estimated gross margins. The… [Read More]

Lisata Secures EMA Waiver for Pancreatic Cancer Treatment

Clinical stage pharmaceutical company, Lisata Therapeutics, Inc. (Nasdaq: LSTA), has reached an agreement with the European Medicines Agency (EMA) on a Pediatric Investigation Plan for Lisata’s lead investigational product, certepetide, in pancreatic cancer. The EMA has agreed to a product-specific full pediatric waiver for certepetide in pancreatic cancer, on the grounds that pancreatic cancer occurs… [Read More]

Aligos Therapeutics Advances “Compelling Potential Treatment Option” in MASH

Aligos Therapeutics, Inc. (Nasdaq: ALGS) has completed enrollment in a Phase 2a clinical study for a metabolic dysfunction-associated steatohepatitis (MASH) therapeutic, with topline safety and efficacy data anticipated in early Q4 2024. The company is evaluating ALG-055009, a best-in-class thyroid hormone receptor beta (THR-ß) agonist, which has demonstrated safety and efficacy in a Phase 1… [Read More]

SunPower (SPWR) Now Sells the Tesla Powerwall 3; Investors Consider It a Bright Idea as Shares Trade Up ~20%

America’s top-rated residential solar energy company, SunPower Corporation (SPWR)  announced it will now offer the Tesla Powerwall 3 as part of its curated selection of high-quality and affordable solar and storage products. “Homeowners are increasingly turning to battery storage to protect themselves against ongoing utility rate hikes and grid outages. We witnessed record-breaking battery storage… [Read More]
Oil pumps under a sunset sky.

Formation Minerals (FOMI) Executes on Strategic Acquisition Strategy Through Recent Sale of Assets

Emerging oil and gas company, Formation Minerals, Inc. (FOMI) announced the sale of five non-core lower performing assets for $140,000 to a private buyer. The sale was completed on May 21, 2024. This highlights the company’s portfolio management abilities and execution of its strategic acquisition strategy. Formation’s strategy focuses on buying low-cost assets that monetize… [Read More]

Stocks making the biggest moves premarket: Target, Lululemon, Shopify and more

Here are the top companies that are drawing attention in the stock market today: Target’s stocks took a tumble of more than 7% in the wake of first-quarter earnings that fell short of expectations. This was due in part to a 3% year-on-year sales decrease as consumers purchased fewer non-essential items. Analog Devices, a semiconductor… [Read More]